These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 26957478)
1. Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer. Backes FJ; Walker CJ; Goodfellow PJ; Hade EM; Agarwal G; Mutch D; Cohn DE; Suarez AA Gynecol Oncol; 2016 May; 141(2):312-317. PubMed ID: 26957478 [TBL] [Abstract][Full Text] [Related]
2. The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1 (ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancer. Zannoni GF; Monterossi G; De Stefano I; Gargini A; Salerno MG; Farulla I; Travaglia D; Vellone VG; Scambia G; Gallo D Hum Pathol; 2013 Jun; 44(6):1047-54. PubMed ID: 23266443 [TBL] [Abstract][Full Text] [Related]
3. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875 [TBL] [Abstract][Full Text] [Related]
4. Tumor-associated macrophage-derived CXCL8 could induce ERα suppression via HOXB13 in endometrial cancer. Tong H; Ke JQ; Jiang FZ; Wang XJ; Wang FY; Li YR; Lu W; Wan XP Cancer Lett; 2016 Jun; 376(1):127-36. PubMed ID: 27018308 [TBL] [Abstract][Full Text] [Related]
5. DNMT3A/3B overexpression might be correlated with poor patient survival, hypermethylation and low expression of ESR1/PGR in endometrioid carcinoma: an analysis of The Cancer Genome Atlas. He D; Wang X; Zhang Y; Zhao J; Han R; Dong Y Chin Med J (Engl); 2019 Jan; 132(2):161-170. PubMed ID: 30614867 [TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification. Guan J; Xie L; Luo X; Yang B; Zhang H; Zhu Q; Chen X J Gynecol Oncol; 2019 Jan; 30(1):e13. PubMed ID: 30479097 [TBL] [Abstract][Full Text] [Related]
7. Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma. Ruz-Caracuel I; López-Janeiro Á; Heredia-Soto V; Ramón-Patino JL; Yébenes L; Berjón A; Hernández A; Gallego A; Ruiz P; Redondo A; Peláez-García A; Mendiola M; Hardisson D Virchows Arch; 2021 Dec; 479(6):1167-1176. PubMed ID: 34420090 [TBL] [Abstract][Full Text] [Related]
8. Dual expression of immunoreactive estrogen receptor β and p53 is a potential predictor of regional lymph node metastasis and postoperative recurrence in endometrial endometrioid carcinoma. Obata T; Nakamura M; Mizumoto Y; Iizuka T; Ono M; Terakawa J; Daikoku T; Fujiwara H PLoS One; 2017; 12(11):e0188641. PubMed ID: 29190668 [TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of DNA topoisomerase II-alpha (Ki-S1) immunoexpression in endometrial carcinoma. Bildrici K; Tel N; Ozalp SS; Yalcin OT; Yilmaz V Eur J Gynaecol Oncol; 2002; 23(6):540-4. PubMed ID: 12556100 [TBL] [Abstract][Full Text] [Related]
10. Molecular clustering of endometrial carcinoma based on estrogen-induced gene expression. Westin SN; Broaddus RR; Deng L; McCampbell A; Lu KH; Lacour RA; Milam MR; Urbauer DL; Mueller P; Pickar JH; Loose DS Cancer Biol Ther; 2009 Nov; 8(22):2126-35. PubMed ID: 19755863 [TBL] [Abstract][Full Text] [Related]
11. [Expression of estrogen receptor-related receptor alpha and estrogen receptor alpha in endometrial carcinoma and the primary investigation of their clinical significance]. Gao M; Wei LH; Sun PM; Zhao D; Li XP Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 38(5):463-5. PubMed ID: 17068614 [TBL] [Abstract][Full Text] [Related]
12. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma. Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659 [TBL] [Abstract][Full Text] [Related]
13. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. Liu Y; Patel L; Mills GB; Lu KH; Sood AK; Ding L; Kucherlapati R; Mardis ER; Levine DA; Shmulevich I; Broaddus RR; Zhang W J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25214561 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance and clinical importance of estrogen receptor alpha and beta in human endometrioid adenocarcinomas. Mylonas I Oncol Rep; 2010 Aug; 24(2):385-93. PubMed ID: 20596625 [TBL] [Abstract][Full Text] [Related]
15. Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer. van Weelden WJ; Lalisang RI; Bulten J; Lindemann K; van Beekhuizen HJ; Trum H; Boll D; Werner HMJ; van Lonkhuijzen LRCW; Yigit R; Forsse D; Witteveen PO; Galaal K; van Ginkel A; Bignotti E; Weinberger V; Sweegers S; Kroep JR; Cabrera S; Snijders MPLM; Inda MA; Eriksson AGZ; ; Krakstad C; Romano A; van de Stolpe A; Pijnenborg JMA Am J Obstet Gynecol; 2021 Oct; 225(4):407.e1-407.e16. PubMed ID: 34019887 [TBL] [Abstract][Full Text] [Related]
16. p53 aberrations in low grade endometrioid carcinoma of the endometrium with nodal metastases: possible insights on pathogenesis discerned from immunohistochemistry. Fadare O; Parkash V Diagn Pathol; 2017 Nov; 12(1):81. PubMed ID: 29137657 [TBL] [Abstract][Full Text] [Related]
17. Identification of microRNA expression profile related to lymph node status in women with early-stage grade 1-2 endometrial cancer. Canlorbe G; Wang Z; Laas E; Bendifallah S; Castela M; Lefevre M; Chabbert-Buffet N; Daraï E; Aractingi S; Méhats C; Ballester M Mod Pathol; 2016 Apr; 29(4):391-401. PubMed ID: 26847173 [TBL] [Abstract][Full Text] [Related]
19. Development of a technique to detect the activated form of the progesterone receptor and correlation with clinical and histopathological characteristics of endometrioid adenocarcinoma of the uterine corpus. Bonneterre J; Hutt E; Bosq J; Graham JD; Powell MA; Leblanc E; Fujiwara K; Herzog TJ; Coleman RL; Clarke CL; Gilles EM; Zukiwski AA; Monk BJ Gynecol Oncol; 2015 Sep; 138(3):663-7. PubMed ID: 26142884 [TBL] [Abstract][Full Text] [Related]
20. Biomarkers and microsatellite instability analysis of curettings can predict the behavior of FIGO stage I endometrial endometrioid adenocarcinoma. Steinbakk A; Malpica A; Slewa A; Skaland I; Gudlaugsson E; Janssen EA; Løvslett K; Fiane B; Kruse AJ; Feng W; Yinhua Y; Baak JP Mod Pathol; 2011 Sep; 24(9):1262-71. PubMed ID: 21552210 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]